- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Gracell Biotechnologies Inc is a biotechnology business based in the US. Gracell Biotechnologies Inc shares (GRCL) are listed on the NASDAQ and all prices are listed in US Dollars. Gracell Biotechnologies Inc employs 314 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Gracell Biotechnologies stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Gracell Biotechnologies Inc stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – GRCL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Gracell Biotechnologies Inc stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 5 of 5
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Gracell Biotechnologies Inc stock price (NASDAQ: GRCL)
Use our graph to track the performance of GRCL stocks over time.Gracell Biotechnologies Inc shares at a glance
Information last updated 2024-06-30.
| 52-week range | $5.28 - $10.44 |
|---|---|
| 50-day moving average | $9.54 |
| 200-day moving average | $5.24 |
| Wall St. target price | $10.58 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.97 |
Is it a good time to buy Gracell Biotechnologies Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gracell Biotechnologies Inc financials
| Gross profit TTM | $366,000 |
|---|---|
| Return on assets TTM | -19.41% |
| Return on equity TTM | -31.57% |
| Profit margin | 0% |
| Book value | $16.90 |
| Market Capitalization | $989.9 million |
TTM: trailing 12 months
Gracell Biotechnologies Inc share dividends
We're not expecting Gracell Biotechnologies Inc to pay a dividend over the next 12 months.
You may also wish to consider:
- Amgen (AMGN.US) (3.48% forward annual dividend yield)
Gracell Biotechnologies Inc share price volatility
Over the last 12 months, Gracell Biotechnologies Inc's shares have ranged in value from as little as $5.28 up to $10.435. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gracell Biotechnologies Inc's is -0.345. This would suggest that Gracell Biotechnologies Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Gracell Biotechnologies Inc has bucked the trend.
To put Gracell Biotechnologies Inc's beta into context you can compare it against those of similar companies.
- Amgen (AMGN.US): 0.599
- BeiGene (BGNE.US): 0.63
- XBiotech (XBIT.US): 1.413
Gracell Biotechnologies Inc overview
Gracell Biotechnologies Inc. , a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.
Frequently asked questions
nullWhat percentage of Gracell Biotechnologies Inc is owned by insiders or institutions?
Currently 16.393% of Gracell Biotechnologies Inc shares are held by insiders and 63.112% by institutions. How many people work for Gracell Biotechnologies Inc?
Latest data suggests 314 work at Gracell Biotechnologies Inc. When does the fiscal year end for Gracell Biotechnologies Inc?
Gracell Biotechnologies Inc's fiscal year ends in December. Where is Gracell Biotechnologies Inc based?
Gracell Biotechnologies Inc's address is: Building 12, Block B, Suzhou, China, 215123 What is Gracell Biotechnologies Inc's ISIN number?
Gracell Biotechnologies Inc's international securities identification number is: US38406L1035
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question